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The G protein-coupled receptor encoded by Kaposi’s sarcoma-associated herpesvirus, also referred to as
ORF74, has been shown to stimulate oncogenic and angiogenic signaling pathways in a constitutively active
manner. The biochemical routes linking ORF74 to these signaling pathways are poorly defined. In this study,
we show that ORF74 constitutively activates p44/p42 mitogen-activated protein kinase (MAPK) and Akt via Gi-
and phospholipase C (PLC)-mediated signaling pathways. Activation of Akt by ORF74 appears to be phos-
phatidylinositol 3-kinase (PI3-K) dependent but, interestingly, is also mediated by activation of protein kinase
C (PKC) and p44/p42 MAPK. ORF74 may signal to Akt via p44/p42 MAPK, which can be activated by Gi,
through activation of PI3-K or through PKC via the PLC pathway. Signaling of ORF74 to these proliferative
and antiapoptotic signaling pathways can be further modulated positively by growth-related oncogene (GRO/
CXCL1) and negatively by human gamma interferon-inducible protein 10 (IP-10/CXCL10), thus acting as an
agonist and an inverse agonist, respectively. Despite the ability of the cytomegalovirus-encoded chemokine
receptor US28 to constitutively activate PLC, this receptor does not increase phosphorylation of p44/p42
MAPK or Akt in COS-7 cells. Hence, ORF74 appears to signal through a larger diversity of G proteins than
US28, allowing it to couple to proliferative and antiapoptotic signaling pathways. ORF74 can therefore be
envisioned as an attractive target for novel treatment of Kaposi’s sarcoma.
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV), also
termed human herpesvirus 8 (HHV-8), is a gammaherpesvirus
that is implicated in the pathogenesis of KS and other prolif-
erative disorders, such as primary effusion B-cell lymphoma
and multicentric Castleman’s disease (13, 15). KS is the most
common malignancy in human immunodeficiency virus-in-
fected individuals but has also been detected in non-human
immunodeficiency virus-infected individuals (25). KS is a
highly angiogenic, multicentric tumor associated with abun-
dant vasculature and spindle cell proliferation. It is believed
that spindle cells are the driving force of KS pathogenesis (25).
However, it is unknown which factor(s) exactly initiates and
sustains spindle cell growth.
The KSHV genome displays an unusual degree of genetic
piracy compared to other herpesviruses (41). Many of its viral
genes encode proteins whose cellular homologues are known
to be involved in growth control, signal transduction, and other
regulatory processes (25). Like several other herpesviruses,
including cytomegalovirus (CMV) (16, 26), HHV-6 and -7 (29,
32, 47), and herpesvirus saimiri (48), KSHV contains a DNA
sequence encoding a protein with homology to cellular G pro-
tein-coupled receptors (GPCRs) (14).
GPCRs play an essential role in cellular communication by
transducing signals through coupling to heterotrimeric G pro-
teins, generating a broad spectrum of physiological responses
(8). It has become clear that various GPCRs induce prolifer-
ation and may induce oncogenic transformation and tumor
formation in pathological conditions (31). Mechanisms in-
volved in GPCR-induced proliferation include, e.g., activation
of mitogen-activated protein kinase (MAPK) signaling path-
ways, including p44/p42, p38, and JNK kinases, and regulation
of cell cycle machinery (30).
The function of virus-encoded GPCRs (vGPCRs) is not fully
understood. vGPCRs show the greatest homology to the family
of chemokine receptors (45, 46), which play a major role in
immune response regulation. Since herpesviruses are associ-
ated with transformation of cells and, along with other factors,
initiate oncogenesis, the GPCRs encoded by these viruses may
be crucial determinants of viral action. The GPCR encoded by
KSHV, also referred to as ORF74, shows the most resem-
blance to the chemokine receptor CXCR2 but, in contrast to
most other cellular chemokine receptors, binds both the CC
and CXC classes of chemokines (4, 46). Remarkably, ORF74
stimulates signaling pathways linked to cell proliferation in an
agonist-independent manner (4). The occurrence of spontane-
ous activity of GPCRs, also referred to as constitutive activity,
is an interesting new concept in GPCR-mediated drug action
(36). Moreover, a variety of human diseases (including some
proliferative disorders) have been ascribed to the constitutive
activity of specific GPCRs due to naturally occurring mutations
(56).
ORF74 constitutively initiates cellular transformation and
tumorigenesis and induces a switch to an angiogenic phenotype
in an agonist-independent manner (5). ORF74 induces the
secretion of vascular endothelial growth factor (VEGF), an
angiogenesis and KS spindle cell growth factor that is likely to
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be involved in sustained growth of spindle cells (5). The ex-
pression of VEGF was found to be associated with ORF74-
induced activation of the p38 and p44/p42 MAPK pathways
(55). Additionally, it has been shown that ORF74 induces
expression of interleukin-1 (IL-1), IL-6, and tumor necrosis
factor alpha in THP-1 cells, bFGF, IL-8, and MCP-1 in human
embryonic kidney (HEK) 293 cells, and IL-2 and IL-4 in Jurkat
cells via activation of NF-B (54). Since ORF74 in KS tumors
is predominantly transcribed in a subpopulation of cells that
express lytic-cycle genes and therefore are unlikely to prolif-
erate, it has been proposed that these paracrine mechanisms
may contribute to KS pathogenesis (33). Recently, transgenic
expression of ORF74 in mice was found to induce angiopro-
liferative lesions resembling KS, further supporting the notion
that ORF74 acts as a viral oncogene, either directly or through
paracrine mechanisms (58).
Although coupling of ORF74 to the MAPK cascade has
been shown (55), little is known about the upstream mecha-
nisms leading to activation of this pathway. In this study, we
show which signaling components are utilized by ORF74 to
activate p44/p42. Moreover, we observed that this pathway is
linked to ORF74-induced signaling to Akt, a pathway impli-
cated in antiapoptotic signaling (22). Activation of these path-
ways occurs in a constitutively active manner by activation of
Gi and phospholipase C (PLC) signaling pathways. Signaling of
ORF74 to p44/p42 MAPK and Akt signaling pathways does
not seem to be universal for vGPCRs, as the CMV-encoded
GPCR US28 does not couple to these pathways. Hence,
ORF74 appears to signal through a larger diversity of G pro-
teins than US28, allowing it to couple to proliferative and
antiapoptotic signaling pathways.
MATERIALS AND METHODS
Materials. Bovine serum albumin, chloroquine diphosphate, DEAE-dextran
(chloride form), pertussis toxin (PTX), and phorbol 12-myristate 13-acetate
(PMA) were obtained from Sigma (St. Louis, Mo.). U0126 was from Tocris
Cookson Ltd. (Bristol, United Kingdom). Bisindolylmaleimide I hydrochloride
(GF-109203X) and wortmannin were obtained from Calbiochem (La Jolla, Cal-
if.). Cell culture media, L-glutamine, penicillin, and streptomycin were obtained
from Life Technologies (Gaithersburg, Md.), and fetal calf serum was purchased
from Integro B.V. (Dieren, The Netherlands). myo-[2-3H]inositol (17 Ci/mmol)
was obtained from Perkin-Elmer Life Sciences. The human chemokines IL-8
(72-amino-acid form), GRO, and human gamma interferon-inducible protein
10 (IP-10) were obtained from PeproTech (Rocky Hill, N.J.).
DNA constructs. The cDNA of HHV-8-encoded ORF74 was a gift from T. W.
Schwartz. The cDNA of ORF74 (GenBank accession number U71368 with a
silent G-to-T mutation at position 927) was inserted into pcDEF3 (a gift from
J. A. Langen) after PCR amplification. The cDNA of US28 (encoded by the
VHL/E human CMV strain; GenBank accession number L20501), inserted into
pcDNA3, was a gift from R. Doms. The cDNA encoding Gt was a gift from B.
Defize.
Cell culture and transfection. COS-7 cells were grown at 5% CO2 and 37°C in
Dulbecco’s modified Eagle’s medium supplemented with 5% fetal calf serum, 2
mM L-glutamine, 50 IU of penicillin per ml, and 50 g of streptomycin per ml.
Transfection of COS-7 cells was performed with DEAE-dextran. The total
amount of DNA in transfected cells was maintained constant by addition of the
empty vector. Transfected cells were maintained in serum-free medium.
[3H]inositol phosphate production. Transfected COS-7 cells were seeded in
24-well plates, and 24 h after transfection they were labeled overnight in inositol-
free medium (modified Eagle’s medium with Earle’s salts) supplemented with 2
mM (each) L-glutamine, L-cysteine, L-leucine, L-methionine, L-arginine, and glu-
cose and 1 Ci of myo-[2-3H]inositol per ml in the presence or absence of PTX
(100 ng/ml). Subsequently, the labeling medium was aspirated, cells were washed
for 10 min with Dulbecco’s modified Eagle’s medium containing 25 mM HEPES
(pH 7.4) and 20 mM LiCl and incubated for 2 h in the same medium in the
presence or absence of the indicated chemokines. The incubation was stopped by
aspiration of the medium and addition of ice-cold 10 mM formic acid. After 90
min of incubation on ice, inositol phosphates were isolated by anion-exchange
chromatography (Dowex AG1-X8 columns; Bio-Rad) and counted by liquid
scintillation.
Binding experiments. IL-8 was labeled with 125I using the Iodogen method
(Pierce, Rockford, Ill.) in accordance with the manufacturer’s protocol with
some minor modifications. Shortly, an Eppendorf tube was coated with Iodogen
by slow evaporation of 50 l of Iodogen solution (1 mg/ml in dichloromethane).
The tube was rinsed with label buffer (125 mM Tris [pH 6.0], 150 mM NaCl).
Subsequently, 5 g of IL-8, 35 l of label buffer, and 0.5 mCi of carrier-free
Na125I (Amersham Pharmacia Biotech Benelux, Roosendaal, The Netherlands)
were added to the tube and incubated for 10 min at room temperature. The
labeling was stopped by addition of 450 l of 20 mM L-tyrosine (Merck KGaA,
Darmstadt, Germany). 125I–IL-8 was separated from free iodine with a 25-cm,
10-ml Sephadex G25 (ICN Pharmaceuticals Inc., Costa Mesa, Calif.) gel filtra-
tion column.
Transiently transfected cells were seeded in 48-well plates. At 48 h after
transfection, binding was performed on whole cells for 3 to 4 h at 4°C using
125I–IL-8 in binding buffer (50 mM HEPES [pH 7.4], 1 mM CaCl2, 5 mM MgCl2,
0.5% bovine serum albumin). Nonspecific binding was determined in the pres-
ence of 0.1 M unlabeled GRO. After incubation, cells were washed four times
with ice-cold binding buffer supplemented with 0.5 M NaCl. Cells were collected
and counted in a Wallac Compugamma counter.
Western blot analysis. Transiently transfected cells were lysed 48 h after
transfection in radioimmunoprecipitation assay (RIPA) buffer (phosphate-buff-
ered saline containing 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.5%
sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium or-
thovanadate, and 2 g each of aprotinin and leupeptin per ml), sonicated,
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and
blotted onto a polyvinylidene difluoride membrane. Antibodies recognizing
p44/42 MAPK, Akt, and phospho-Akt (S473) (New England Biolabs, Inc., Bev-
erly, Mass.) were used in combination with a goat anti-rabbit horseradish per-
oxidase-conjugated secondary antibody (Bio-Rad). The antibody recognizing
phospho-p44/42 MAPK (T202/Y204) (New England Biolabs, Inc.) was used in
combination with a goat anti-mouse horseradish peroxidase-conjugated second-
ary antibody (Bio-Rad). Protein bands were detected by an enhanced-chemilu-
minescence assay and directly quantified with an Image station (NEN Life
Science Products, Inc., Boston, Mass.).
RESULTS
Agonist-independent activation of inositol phosphate pro-
duction. As previously reported (4, 52), increased expression of
ORF74 in COS-7 cells, as shown by an increase in specific
125I–IL-8 binding, resulted in expression-dependent enhance-
ment of [3H]inositol phosphate (InsP) production, measured
in the absence of any ligand (Fig. 1A and B). This constitutive
activity of ORF74 can be further increased by the agonist
GRO (CXCL1, 100 nM) and can be inhibited by the inverse
agonist IP-10 (CXCL10, 100 nM) (Fig. 1A, inset), as was
shown by others (27, 28). Expression of the cellular homologue
of ORF74, CXCR2, did not induce InsP production in either
the absence or the presence of IL-8 (CXCL8, 100 nM) (data
not shown). Expression of the constitutively active CMV-en-
coded GPCR US28 (12) resulted in an increase in InsP pro-
duction comparable to that observed with ORF74 (Fig. 1A).
Agonist-independent activation of p44/p42 MAPK activity.
Since ORF74 is known to induce cellular transformation (5)
and regulates expression of VEGF through activation of, e.g.,
p44/p42 MAPK (55), we examined the mechanisms involved in
the activation of p44/p42 MAPK. Expression of ORF74 re-
sulted in an increase in basal endogenous MAPK activity as
detected by an increase in phosphorylation of p44/p42 MAPK,
measured by using an antibody recognizing the phosphorylated
form of p44/p42 MAPK (Fig. 2A). Interestingly, US28 was not
able to induce an increase in MAPK phosphorylation (Fig.
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2A). The ORF74-induced phosphorylation of MAPK can be
further increased by incubation with GRO (CXCL1, 30 nM)
and inhibited by exposure to IP-10 (CXCL10, 100 nM) (Fig.
2B). Incubation of COS-7 cells expressing ORF74 with the
MEK inhibitor U0126 (10 M) led to complete abolishment of
MAPK phosphorylation, confirming the involvement of the
Raf-MEK pathway (Fig. 2D).
Since Gershengorn and colleagues have shown that NIH
3T3 cells expressing ORF74 induce tumor formation when
injected into nude mice (5), we investigated the activation of
p44/p42 MAPK by ORF74 in these cells also. ORF74 induced
p44/p42 MAPK phosphorylation both constitutively and after
incubation with GRO (138%  0.5% and 298%  106% over
mock-transfected cells, respectively) in NIH 3T3 cells.
Both Gi- and Gq-coupled receptors are known to activate
MAPK in COS-7 cells (18, 38, 39). MAPK activation by Gi-
coupled receptors has been reported to be mediated by G
subunits, leading to activation of PI3-K and Ras (34). Since
ORF74 has been shown to couple to Gi proteins (10, 17, 40),
the involvement of Gi in ORF74-induced MAPK activation
was investigated. Pretreatment of cells with PTX (100 ng/ml,
48 h) resulted in a 64% reduction of an ORF74-induced in-
crease in MAPK phosphorylation (Fig. 2C), indicating the
involvement of Gi proteins. Coexpression of Gt, which is
known to scavenge G subunits, also led to a reduction (67%)
in ORF74-induced phosphorylation of MAPK. Finally, the in-
volvement of PI3-K was indicated by a 75% reduction of
ORF74-induced phosphorylation of MAPK produced by pre-
treatment of cells for 2 h with wortmannin (100 nM) (Fig. 2C).
Receptors coupled to the PTX-insensitive Gq/11 family acti-
vate p44/p42 MAPK via activation of protein kinase C (PKC),
which is known to stimulate Raf-1 independently of Ras (39).
Since ORF74 stimulates PLC, thereby generating DAG, which
is known to activate PKC, this kinase is likely to play a role in
the ORF74-induced signaling to MAPK. As expected, down-
regulation of PKC by long-term treatment with the PKC acti-
vator PMA (100 nM, 48 h) or inhibition of PKC by preincu-
bation of cells with the specific PKC inhibitor bisindolylmaleimide
(1 M) resulted in marked attenuation (70 and 75%, respec-
tively) of the ORF74-induced increase in MAPK activity (Fig.
2D). Both treatments completely abolished MAPK activation
by PMA (5 min, 1 M) (data not shown).
Agonist-independent activation of Akt by ORF74. The
serine/threonine kinase Akt has been shown to be implicated
in signaling pathways leading to cell survival (22). ORF74
expression resulted in a marked increase in phosphorylation of
a key regulatory serine residue in the carboxyl-terminal tail of
endogenous Akt in COS-7 cells, as evidenced by immunoblot-
ting with a phosphospecific antibody (Fig. 3A). US28 expres-
sion, on the other hand, did not influence phosphorylation of
Akt (Fig. 3A). As anticipated, the constitutive increase in Akt
phosphorylation caused by ORF74 can be further increased by
the agonist GRO (CXCL1, 30 nM) and inhibited by the
inverse agonist IP-10 (CXCL10, 100 nM) (Fig. 3B). Little is
known about the mechanisms involved in signaling of GPCRs
to Akt. Involvement of Gi signaling pathways in the ORF74-
induced signaling to Akt was ascertained by treatment with
PTX. As can be seen in Fig. 3C, PTX treatment resulted in
inhibition (72%) of ORF74-induced phosphorylation of Akt.
Inhibition of ORF74-induced Akt phosphorylation by coex-
pression of Gt was similarly attenuated (70%), suggesting the
involvement of G subunits in signaling of ORF74 to Akt
(Fig. 3C). Since PI3-K is known to activate Akt (23), ORF74-
expressing cells were treated with wortmannin. As expected,
inhibition of PI3-K activity resulted in total abolishment of
ORF74-induced phosphorylation of Akt (Fig. 3C). Basal Akt
FIG. 1. ORF74-mediated induction of inositol phosphate accumulation. (A) COS-7 cells (106 cells) were transiently transfected with increasing
amounts of cDNA encoding ORF74 or a single amount of cDNA encoding US28 (2 g/106 cells). At 48 h after transfection, inositol phosphate
accumulation was measured. (Inset) Stimulation and inhibition of ORF74-induced inositol phosphate accumulation by the agonist GRO (100 nM,
2 h) and the inverse agonist IP-10 (100 nM, 2 h), respectively. (B) COS-7 cells (106 cells) were transiently transfected with increasing amounts of
cDNA encoding ORF74, and 125I–IL-8 binding was performed as described in Materials and Methods. Data are presented as percentages of the
values of control (mock-transfected) cells. Representative experiments performed in triplicate are shown. Each experiment was done at least three
times.
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phosphorylation levels in mock-transfected cells were also af-
fected by wortmannin treatment (data not shown). During the
preparation of this report, Montaner et al. (40) showed the
involvement of Gi, G subunits, and PI3-K in ORF74-induced
activation of Akt by using transiently transfected, hemaggluti-
nin-tagged Akt in COS-7 cells.
As previously shown by others, mutationally activated H-Ras
(RasQL), which is known to activate endogenous PI3-K, also
induced phosphorylation of Akt in COS-7 cells (Fig. 3D) (7,
40, 44). Interestingly, incubation of cells with the MEK inhib-
itor U0126 (10 M) resulted in marked (86%) inhibition of
ORF74-induced phosphorylation of Akt (Fig. 3E). Since
FIG. 2. ORF74-induced activation of p44/p42 MAPK. (A) Effect of ORF74 (0.5 g/106 cells) and US28 (2.0 g/106 cells) on the basal
phosphorylation of p44/p42 MAPK in transiently transfected COS-7 cells as determined by Western blot analysis using specific anti-phosho-p44/
p42 (P-p44/p42) antibodies. Phosphorylation was quantified by chemiluminescence and corrected for total MAPK (T-p44/p42) expression on
stripped blots. Data are presented as fold control (mock-transfected) cell values. (B) Transiently transfected COS-7 cells were incubated with IP-10
(100 nM, 48 h) or with GRO (30 nM, 5 min) before the cells were lysed. (C) Involvement of the Gi signaling pathway in ORF74-induced p44/p42
MAPK phosphorylation. COS-7 cells transiently transfected with ORF74 alone (0.5 g/106 cells) or cotransfected with Gt (1 g/10
6 cells) were
grown in serum-free medium in the presence or absence of PTX (100 ng/ml, 48 h) or the PI3-K inhibitor wortmannin (WM) (100 nM, 2 h) before
lysis and Western blot analysis. Data are presented as the percentage of ORF74-induced p44/p42 MAPK phosphorylation in at least three
independent experiments, and representative blots are shown. (D) Role of the PLC signaling pathway in constitutive phosphorylation of p44/p42
MAPK by ORF74. COS-7 cells transiently transfected with ORF74 (0.5 g/106 cells) were grown in serum-free medium in the presence or absence
of the MEK1/2 inhibitor U0126 (10 M, 2 h), the PKC inhibitor bisindolylmaleimide I (Bis; 1 M, 2 h), or the phorbol ester PMA (100 nM, 48 h)
before lysis and Western blot analysis. Data are presented as the percentage of ORF74-induced p44/p42 MAPK phosphorylation in at least two
independent experiments, and representative blots are shown.
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ORF74 is able to activate p44/p42 MAPK through activation of
PKC, we examined the involvement of PKC in the ORF74-
induced phosphorylation of Akt. Treatment of mock-trans-
fected cells with PMA (5 min, 1 M) led to an increase in the
phosphorylation of endogenous Akt, implying the involvement
of PKC in the phosphorylation of Akt (Fig. 3D). Downregu-
lation of PKC (treatment of cells for 48 h with PMA at 100
nM) indeed inhibited (63%) ORF74-induced phosphorylation
of Akt, suggesting the involvement of PLC-mediated signaling
of ORF74 to Akt (Fig. 3E).
DISCUSSION
There is compelling evidence that ORF74 activates onco-
genic and angiogenic signaling pathways (5, 55, 58). ORF74
may therefore be a key determinant in the development of KS.
Since ORF74 is expressed in only a small subpopulation of KS
spindle cells (33), it has been suggested that ORF74 initiates
tumorigenesis via indirect mechanisms, e.g., through produc-
tion of growth factors and cytokines that act in a paracrine
manner (54, 55). Activation of the transcription factor NF-B
through the PI3-K/Akt pathway was reported to be involved in
the ORF74-induced secretion of IL-6, IL-8, and RANTES in
KSIMM cells, an HHV-8-negative KS-derived cell line (49).
However, the mechanisms underlying signaling of ORF74 to
oncogenic and angiogenic pathways are poorly defined. Earlier
studies of ORF74 linked this G protein-coupled receptor to
activation of JNK and p38 MAPK signaling pathways when
expressed in HEK 293 cells (5). Recent studies showed that
besides activation of p38 MAPK, ORF74 also activates p44/
p42 MAPK signaling pathways when expressed in COS-7 cells,
leading to expression of VEGF via activation of the transcrip-
tion factor hypoxia-inducible factor 1 (55). In this report, we
describe the upstream mechanisms responsible for the ORF74-
induced activation of p44/p42 MAPK. In addition, we show
that ORF74 constitutively phosphorylates Akt, which is known
to be involved in antiapoptotic signaling (22).
ORF74, unlike its cellular homologue CXCR2, initiates for-
mation of InsP in a constitutively active manner when ex-
pressed in COS-7 cells, as was previously shown by others (4,
52). Activation of PLC by ORF74 is likely mediated via stim-
ulation of Gq-mediated signaling pathways, although no direct
evidence of this has been presented so far (4, 12, 52). p44/p42
MAPK is an important mediator of proliferative signaling,
transducing the signal from the cell surface to the nucleus (31).
Gi-coupled receptors are known to activate p44/p42 MAPK via
G subunits involving PI3-K and Ras, while Gq-coupled re-
ceptors activate MAPK via Raf-1 through a PKC-dependent
pathway independently of G and Ras (18, 38, 39). In this
study, we show that ORF74 utilizes both pathways to activate
p44/p42 MAPK, since inhibition of Gi, scavenging of G sub-
units, and inhibition of PKC activity markedly suppressed
ORF74-induced activation of MAPK (Fig. 4). As expected,
both MEK and PI3-K are key players in the ORF74-induced
signaling to p44/p42 MAPK.
Earlier studies in our laboratory showed that the CMV-
encoded chemokine receptor US28, like ORF74, constitutively
activates PLC (12). Interestingly, in COS-7 cells, the CMV-
FIG. 3. ORF74-induced activation of Akt. (A) Effects of ORF74 (0.5 g/106 cells) and US28 (2.0 g/106 cells) on the basal phosphorylation
of Akt in transiently transfected COS-7 cells as determined by Western blot analysis using specific anti-phosho-Akt (P-Akt) antibodies. Phos-
phorylation was quantified by chemiluminescence and corrected for total Akt (T-Akt) expression on stripped blots. (B) Regulation of the
ORF74-induced constitutive phosphorylation of Akt by IP-10 (100 nM, 48 h) and GRO (30 nM, 5 min) in transiently transfected COS-7 cells.
Data are presented as fold control (mock-transfected) cell values. Representative blots are shown. Each experiment was done at least three times.
(C) Involvement of the Gi signaling pathway in ORF74-induced constitutive Akt phosphorylation. COS-7 cells transiently transfected with ORF74
alone (0.5 g/106 cells) or cotransfected with Gt (1 g/10
6 cells) were grown in serum-free medium in the presence or absence of PTX (100 ng/ml,
48 h) or the PI3-K inhibitor wortmannin (WM; 100 nM, 2 h) before lysis and Western blot analysis. Data are presented as the percentage of
ORF74-induced Akt phosphorylation of at least two independent experiments, and representative blots are shown. (D) Akt phosphorylation by
mutationally activated H-Ras and via activation of PKC. COS-7 cells were transiently transfected with mutationally activated H-Ras (1 g/106 cells)
or empty vector and grown in serum-free medium for 48 h. PMA-treated cells were incubated with PMA (1 M) 5 min before lysis. (E) Role of
the PLC signaling pathway in constitutive phosphorylation of Akt by ORF74. COS-7 cells transiently transfected with ORF74 (0.5 g/106 cells)
were grown in serum-free medium in the presence or absence of the MEK1/2 inhibitor U0126 (10 M, 2 h) or the phorbol ester PMA (100 nM,
48 h) before lysis and Western blot analysis. Data are presented as the percentage of ORF74-induced Akt phosphorylation in at least two
independent experiments, and a representative blot is shown.
FIG. 4. Hypothetical scheme of signal transduction pathways acti-
vated by ORF74. Based on data from this study, activation of p44/p42
MAPK by ORF74 seems to be Gi mediated via G subunits involving
PI3-K and PLC dependent via activation of PKC, presumably at the
level of Raf-1 (39). Activation of Akt by ORF74 appears to be PI3-K
dependent, likely via G from Gi, and seems also to be mediated by
activation of the PKC and Ras-Raf pathways.
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encoded GPCR US28, which is homologous to CC chemokine
receptors, does not activate p44/p42 MAPK, even though
US28 constitutively activates the production of InsP to an
extent similar to that of ORF74. Yet, an earlier report de-
scribed US28-mediated activation of p44/p42 MAPK by the
CC chemokine RANTES (CCL5) in HEK 293 cells (6). In
contrast, ORF74, preferentially binding CXC chemokines,
does not activate p44/p42 MAPK signaling pathways when
expressed in HEK 293 cells (5) while it does so when expressed
in COS-7 and NIH 3T3 cells, as was shown in this study and by
others (55). It therefore seems that the cell type rather than the
chemokine family determines the ability of chemokine(-like)
receptors to activate p44/p42 MAPK. The fact that US28 does
not couple to the same broad range of signaling pathways as
ORF74 when expressed in COS-7 cells (12) may account for its
inability to activate p44/p42 MAPK.
Cellular transformation is often associated with the activa-
tion of antiapoptotic signaling pathways. Recently, cell type-
specific activation of Akt by some GPCRs has been shown (42,
43, 53). Akt has been found to be an important intermediate in
cell survival and in the control of apoptosis by regulation of
several downstream effectors, including activation of Bad (20,
21), Forkhead (9), GSK3 (19), and transcription factors such as
CREB (50) and NF-B (51). Activation of CREB and NF-B
may lead to expression of factors implicated in the pathogen-
esis of KS. However, the signaling pathways linking GPCRs to
Akt have been poorly characterized. PI3-K appears to be an
important upstream activator of Akt since pharmacological
inhibitors of PI3-K such as wortmannin abrogate activation of
Akt (11, 24, 35). Moreover, constitutively active Ras (H-Ras),
which is known to activate PI3-K, is able to activate Akt (40,
44). It is believed that the PI3-K phospholipid products
PI(3,4,5)P3 and PI(3,4)P2 are responsible for the translocation
of Akt, PDK-1, and yet to be identified PDK2 to the plasma
membrane (3). As a consequence, these kinases phosphorylate
Akt on the regulatory threonine 308 and serine 473 residues,
respectively (2). However, activation of Akt via a PI3-K-inde-
pendent pathway in response to cyclic AMP has also been
reported but no mechanistic information is available (53).
Conflicting data exist about immediate signaling partners
involved in GPCR-mediated activation of Akt. In one study,
constitutively active Gq was found to activate transiently
transfected Akt in COS-7 cells (44) while another showed an
inhibitory effect of Gq on G (G12 or G22)- and H-Ras-
mediated activation of Akt (7). The authors of the latter report
therefore proposed that G proteins can regulate Akt by two
distinct and opposing mechanisms.
In this study, we show that ORF74 constitutively phosphor-
ylates endogenous Akt in COS-7 cells. As expected, PI3-K,
which is likely to be activated via the release of G subunits
upon interaction of ORF74 with Gi proteins, is fully implicated
in the activation of Akt in ORF74-expressing cells. As de-
scribed earlier by Gutkind and colleagues, the PI3-K-isoform
present in COS-7 cells is the likely candidate responsible for
signaling of GPCRs to Akt (43). Interestingly, our paper re-
ports, to our knowledge, for the first time that downstream
signaling components of the Ras-Raf pathway also play a role
in the signaling of a GPCR to Akt, as preincubation of cells
with the MEK inhibitor U0126 inhibited ORF74-induced
phosphorylation of Akt (Fig. 4). ORF74 may signal to Akt via
p44/p42 MAPK, which can be activated by Gi through activa-
tion of PI3-K or through PKC via the PLC-dependent pathway
(Fig. 4). Ectopic expression of PKC-, which is present in
COS-7 cells (1), has been reported to increase activation of
Akt in myeloid progenitor and COS-1 cells (37, 57), suggesting
the ability of endogenous PKC- to activate Akt in COS-7
cells. Indeed, inhibition of PKC abrogates not only ORF74-
induced activation of p44/p42 MAPK but also Akt. In COS-7
cells, the observed phosphorylation of Akt by direct stimula-
tion of PKC is limited, suggesting that ORF74 utilizes addi-
tional signal transduction pathways to ensure optimal stimula-
tion of Akt. Early studies by Gutkind and colleagues failed to
show PKC-dependent activation of Akt directly or in signaling
from the muscarinic m1 receptor and Gq to Akt (44). This
discrepancy may be explained by the fact that we studied
ORF74-induced phosphorylation of endogenous Akt while
others transiently coexpress Akt-1, an isoform with regulatory
properties that are possibly different from those of the endog-
enous Akt isoform(s) present in COS-7 cells. Although we
observed constitutive activation of p44/p42 MAPK by ORF74
in NIH 3T3 cells, we could not detect constitutive activation of
Akt by ORF74 in these cells (unpublished observations). This
may be explained by the presence of different Akt isoforms in
these cells. Additional experiments need to be performed to
further delineate the mechanisms by which downstream signal-
ing components of the Ras-Raf pathway signal to Akt and
whether PKC activates Akt via p44/p42 MAPK or by other
means.
Despite the constitutive activation of PLC by US28, no in-
crease in Akt phosphorylation is observed in US28-transfected
cells. These observations are in line with our findings that
US28 also does not activate p44/p42 MAPK, which plays an
important role in the signaling of ORF74 to Akt. Alternatively,
preferred coupling of US28 to the Gq pathway rather than the
Gi pathway in COS-7 cells (12), along with the fact that Gq has
been shown to inhibit Akt-induced signaling (7), may be an-
other explanation for the inability of US28 to activate Akt.
Hence, by virtue of the ability of ORF74 to activate various
distinct G proteins, ORF74 initiates an array of signaling path-
ways that interact to generate an integrated response. Further
studies are required to delineate the mechanisms underlying
signaling of ORF74 to proliferative and antiapoptotic signaling
systems in more physiological cellular systems. However, our
studies clearly indicate that ORF74 signals to these pathways
in a constitutively active manner. Moreover, not only does
ORF74 constitutively activate p44/p42 MAPK and Akt but its
activity can also be modulated positively by GRO (CXCL1)
and negatively by IP-10 (CXCL10), thus acting as an agonist
and an inverse agonist, respectively. By virtue of its ability to
respond either positively or negatively to these chemokines,
ORF74 can influence proliferative and antiapoptotic signaling,
depending on the presence of endogenously expressed chemo-
kines.
During the preparation of this report, Gutkind and col-
leagues reported the ability of ORF74 to promote endothelial
cell survival through activation of Akt-1 (40). Similar to one of
the pathways linking ORF74 to Akt in this study, Gutkind and
colleagues found ORF74-induced signaling to Akt-1 in COS-7
cells to be partially inhibited by PTX and dependent on PI3-K
and G subunits. Based on the data presented in this report,
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the PLC-dependent PKC activation and p44/42 MAPK activa-
tion seem to play important roles as well.
Taken together, the data available indicate that ORF74 con-
stitutively activates proliferative and antiapoptotic signaling
pathways via Gi and PLC. The fact that ORF74 stimulates a
broad range of signaling pathways accounts for the fact that
this receptor, but not the CMV-encoded chemokine receptor
US28, activates p44/p42 and Akt signaling pathways. Activa-
tion of p44/42 MAPK may play a significant role in ORF74-
induced oncogenesis or induction of angiogenesis via expres-
sion of VEGF (55). Since transforming viruses require survival
of infected cells to initiate oncogenesis, ORF74-mediated ac-
tivation of antiapoptotic signaling pathways through activation
of Akt may be of physiological relevance as well. ORF74 can
be envisioned as an attractive target for the treatment of KS.
Development of small ligands acting at this receptor is essen-
tial for further substantiation of the importance of this recep-
tor in the viral action of KSHV.
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